Radboud University
Company
Radboud University develops one asset, in phase 3 (Sonlicromanol in m.3243A>G-related primary mitochondrial disease). Mostly small molecule acting on oxidative phosphorylation, Oxidative stress and ROS signalling and inflammation.
- 1
- Asset
- Furthest stage
- Phase 3
- 8
- Grants
- 72
- Trials
- 0
- Signals
Pipeline
1Modulates reductive and oxidative distress with anti-inflammatory properties; its active metabolite inhibits microsomal prostaglandin E synthase-1.
Phase 3, Small molecule, Oxidative phosphorylation, Oxidative stress and ROS signalling, m.3243A>G-related primary mitochondrial disease, maternally inherited diabetes and deafness, Partner
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
1Radboud University Medical Center
1 asset, 72 trials
In the full profile
- Evidence behind the mechanisms5
- Trials90
- People7
- Integrity notices10
- Similar companies6